Inclusion Criteria:
- - Subjects must meet all the following inclusion criteria to be eligible to enroll in
this study.
1. Has a diagnosis of MM based on standard criteria as follows:
Major criteria:
1. Plasmacytomas on tissue biopsy. 2. BM plasmacytosis (greater than 30% plasma cells)
3. Monoclonal immunoglobulin spike on serum electrophoresis IgG greater than 3.5
g/dL or IgA greater than 2.0 g/dL or kappa or lambda light chain excretion
greater than 1 g/day on 24-hour urine protein electrophoresis. Minor criteria:
1. BM plasmacytosis (10% to 30% plasma cells)
2. Monoclonal immunoglobulin present but of lesser magnitude than given under major
criteria. 3. Lytic bone lesions. 4. Normal IgM less than 50 mg/dL, IgA less than 100 mg/dL, or IgG less than 600
mg/dL. Any of the following sets of criteria will confirm the diagnosis of multiple myeloma:
- - any 2 of the major criteria.
- - major criterion 1 plus minor criterion 2, 3, or 4.
- - major criterion 3 plus minor criterion 1 or 3.
- - minor criteria 1, 2, and 3, or 1, 2, and 4.
2. Currently has MM with measurable disease, defined as:
- - a monoclonal immunoglobulin spike on serum electrophoresis of at least 0.5 g/dL and/or
urine monoclonal protein levels of at least 200 mg/24 hours.
- - for patients without measurable serum and urine M-protein levels, an involved SFLC >
100 mg/L or abnormal SFLC ratio.
- - for patients with IgD MM, a monoclonal immunoglobulin IgD of at least 5500 mg/L or
meet other measurable disease eligibility criteria.
3. Currently has progressive MM and has received at least 2 prior regimens including
lenalidomide, a proteasome inhibitor, and an anti-CD38 antibody:
- - Patients are considered relapsed when they progress greater than 8 weeks from their
last dose of treatment.
- - Patients are refractory when they progress while currently receiving the treatment or
within 8 weeks of its last dose.
4. Ruxolitinib naïve. 5. Understand and voluntarily sign an informed consent form before receiving any
study-related procedure that is not part of normal medical care, with the
understanding that consent may be withdrawn at any time without prejudice to their
future medical care. 6. Able to adhere to the study visit schedule and other protocol requirements. 7. ECOG performance status of ≤ 2 at study entry. 8. Life-expectancy of greater than 3 months. 9. Laboratory test results within these ranges at Screening and confirmed at
enrollment prior to drug dosing on Cycle 1, Day 1:
- - Absolute neutrophil count ≥ 1.5 x 109/L.
o If the bone marrow is extensively infiltrated (≥ 70% plasma cells) then ≥ 1.0 x
109/L.
- - Platelet count ≥ 75 x 109/L.
o Patients must not have received platelet transfusion for at least 7 days prior to
receiving screening platelet count.
- - If the bone marrow is extensively infiltrated (≥ 70% plasma cells) then ≥ 50 x
109/L.
- - If patient have creatinine clearance of less than 60mL/min, patient's platelet
count must be greater than 150 x 109/L.
- - Hemoglobin ≥ 8.0 g/dL within 21 days prior to enrollment.
o Use of erythropoietic stimulating factors and red blood cell (RBC) transfusions per
institutional guidelines is allowed; however, most recent RBC transfusion must have
been at least 7 days prior to obtaining screening hemoglobin.
- - Calculated or measured CrCl > 60 mL/minute per Cockcroft-Gault (Appendix 3)
- Total bilirubin levels ≤ 2.0 mg/dL.
- - AST (SGOT) and ALT (SGPT) ≤ 2 x ULN.
- - Serum potassium 3.0 - 5.5 mEq/L.
10. Patients receiving lenalidomide (Part 2 of the study) must be registered into the
mandatory REVLIMID REMS™ program, and be willing and able to comply with the
requirements of the REVLIMID REMS™ program. 11. FCBP† must have a negative serum or urine pregnancy test with a sensitivity of at
least 25 mIU/mL within 10
- - 14 days prior to and again within 24 hours of starting
ruxolitinib + methylprednisolone and must either commit to continued abstinence from
heterosexual intercourse or use acceptable methods of birth control, one highly
effective method and one additional effective method AT THE SAME TIME, and at least 28
days before she starts taking ruxolitinib with or without lenalidomide.
FCBP must also
agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual
contact with a FCBP even if they have had a vasectomy. All subjects must be counseled
at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
†A FCBP (female of childbearing potential) is a sexually mature woman who: 1) has not
undergone a hysterectomy or bilateral oophorectomy; and 2) has not been naturally
postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in
the preceding 24 consecutive months)
12. Able to take antiplatelet therapy if platelet count is above 30 x 109/L. Options
include aspirin (acetylsalicylic acid, ASA) at 81 or 325 mg/daily and warfarin or low
molecular weight heparin if ASA-intolerant.
Exclusion Criteria:
- - Subjects meeting any of the following exclusion criteria are not to be enrolled in the
study:
1.
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein,
and skin changes)
2. Plasma cell leukemia (> 2.0 × 109/L circulating plasma cells by standard
differential)
3. Primary amyloidosis. 4. Non-hematologic malignancy within the past 5 years with the exception of a)
adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid
cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of
Gleason Grade 6 or less with stable prostate-specific antigen levels; or d)
cancer considered cured by surgical resection or unlikely to impact survival
during the duration of the study, such as localized transitional cell carcinoma
of the bladder or benign tumors of the adrenal or pancreas. 5. Patients with uncontrolled infections. 6. Impaired cardiac function or clinically significant cardiac diseases, including
any one of the following:
- - Myocardial infarction within 6 months prior to enrollment.
- - New York Heart Association (NYHA) Class II or greater heart failure or
uncontrolled angina.
- - Clinically significant pericardial disease.
- - Severe uncontrolled ventricular arrhythmias.
- - Echocardiogram or MUGA evidence of LVEF below institutional normal within 28
days prior to enrollment.
- - Electrocardiographic evidence of acute ischemia or active conduction system
abnormalities.
Prior to study entry, any ECG abnormality at Screening must
be documented by the investigator as not medically relevant.
- - Severe hypercalcemia, i.e., serum calcium ≥ 12 mg/dL (3.0 mmol/L) corrected
for albumin.
7. Any serious medical condition, laboratory abnormality, or psychiatric illness
that would prevent the subject from signing the informed consent form. 8. Any condition, including the presence of laboratory abnormalities, which places
the subject at unacceptable risk if he/she were to participate in the study or
confounds the ability to interpret data from the study. 9. Undergone major surgery within 28 days prior enrollment or has not recovered from
side effects of such therapy (vertebroplasty or kyphoplasty is not considered to
be a major surgery; however, the investigator is to discuss enrollment of a
subject with a recent history of kyphoplasty with the medical monitor).
10. Pregnant or breastfeeding females (lactating females must agree not to breast
feed while taking lenalidomide)
11. Received the following prior therapy:
- - Chemotherapy within 3 weeks of study drugs.
- - Corticosteroids (>20 mg/daily prednisone or equivalent) within 3 weeks of
study drugs to ensure that steroid dose intensity at the beginning of the
treatment is not altered by administration of steroids prior to the study.
Consumption of steroids within 3 weeks of the treatment may interfere with
efficacy and side effects due to differences of steroid intensity.
- - Immunotherapy, antibody therapy, immunomodulatory drugs, or proteasome
inhibitors within 3 weeks of study drugs.
- - Extensive radiation therapy within 28 days before study drugs.
Receipt of
localized radiation therapy does not preclude enrollment.
- - Use of any other experimental drug or therapy within 28 days of study drugs.
- - JAK inhibitor including ruxolitinib.
12. Strong CYP3A4 inhibitors, strong CYP3A4 inducers and fluconazole doses >200 mg
daily within 5 half-lives before study drugs. (For example, clarithromycin has
half-life of 4 hours so washout period for clarithromycin is 20 hours.)
13. Known hypersensitivity to compounds of similar chemical or biological composition
to thalidomide and lenalidomide or steroids.
14. Concurrent use of other anti-cancer agents or treatments. 15. The development of erythema nodosum if characterized by a desquamating rash while
taking thalidomide or similar drugs. 16. Known positivity for human immunodeficiency virus (HIV), hepatitis B or C, and
/or active tuberculosis (TB) including subjects with latent TB or with the risk
factor for activation of latent TB.
